Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice

Liver International

Volumn 31, Issue 1, 2011, Pages 52-64

  Amigo, Ludwig ^a   Husche, Constanze ^b   Zanlungo, Silvana ^a   Lütjohann, Dieter ^b   Arrese, Marco ^a   Miquel, Juan Francisco ^a   Rigotti, Attilio ^a   Nervi, Flavio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cholecystectomy; Gallbladder; Hepatic fatty acid and triglyceride metabolism; VLDL production

Indexed keywords

APOLIPOPROTEIN B; BILE ACID; FATTY ACID; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CHOLECYSTECTOMY; CONTROLLED STUDY; FATTY ACID SYNTHESIS; GENE EXPRESSION; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOLYSIS; LIVER; MALE; MOUSE; NONHUMAN;

ACYL-COA OXIDASE; ANIMALS; APOLIPOPROTEINS B; BILE ACIDS AND SALTS; CARRIER PROTEINS; CHOLECYSTECTOMY; CHOLESTEROL; CYTOCHROME P-450 CYP3A; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPOLYSIS; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, INBRED C57BL; NIACIN; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIME FACTORS; TRIGLYCERIDES; UP-REGULATION;

EID: 78650107030     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02361.x     Document Type: Article

References (77)

1. Ganong WF. Review of Medical Physiology. Columbus, OH: McGraw-Hill Companies, 2005; 467-79.
2. Dawson PA. Bile secretion and the enterohepatic circulation. In: Feldman M, Friedman LS, Brandt LJ, eds. Gastrointestinal and Liver Disease. Pathophysiology, Diagnosis and Treatment. Philadelphia, PA: Saunders Elsevier, 2006; 1369-85.
3. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 1253-5.
4. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
5. Frayn KN, Arner P, Yki-Järvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem 2006; 42: 89-103.
6. Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu Rev Physiol 2010; 72: 315-33.
7. Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006; 20: 981-96.
8. Grundy SM. Metabolic complications of obesity. Endocrine 2000; 13: 155-65.
9. Grundy SM. Cholesterol gallstones: a fellow traveller with metabolic syndrome? Am J Clin Nutr 2004; 80: 1-2.
10. Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006; 45: 299-305.
11. Krondl A, Vavrinková H, Michalec C. Effect of cholecystectomy on the role of the gall bladder in fat absorption. Gut 1964; 5: 607-10.
12. Almond HR, Vlahcevic ZR, Bell CC Jr, Gregory DH, Swell L Jr. Bile acid pools and biliary lipid composition before and after cholecystectomy. N Engl J Med 1973; 289: 1213-6.
13. Roda E, Aldini R, Mazzella G, et al. Enterohepatic circulation of bile acids after cholecystectomy. Gut 1978; 19: 640-9.
14. Kullak-Ublick G-A, Paumgartner G, Berr F. Long-term effects of cholecystectomy on bile acid metabolism. Hepatology 1995; 21: 41-5.
15. Shaffer EA, Small DM. Biliary lipid secretion in cholesterol gallstone disease. The effect of cholecystectomy and obesity. J Clin Invest 1977; 59: 828-40.
16. Pomare EW, Heaton KW. Bile salt metabolism in patients with gallstones in functioning gallbladders. Gut 1973; 14: 885-90.
17. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25: 1419-25.
18. Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007; 18: 289-97.
19. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-91.
20. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-4.
21. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 729-35.
22. Tomlinson E, Fu L, John L, Hultgren B, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-7.
23. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-603.
24. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 2008; 5: 42-8.
25. Repa JJ, Lund EG, Horton JD, et al. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J Biol Chem 2000; 275: 39685-92.
26. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44.
27. Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE.3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 2004; 24: 768-74.
28. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110: 109-17.
29. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94-121.
30. Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438-44.
31. Färkkilä M, Miettinen TA. Lipid metabolism in bile acid malabsorption. Ann Med 1990; 22: 5-13.
32. Carrella M, Ericsson S, Del Piano C, Angelin B, Einarsson K. Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men. J Intern Med 1991; 229: 241-6.
33. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991; 40 (Suppl. 1): S53-8.
34. Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridemia. Lancet 1974; 2: 929-31.
35. Angelin B, Leijd B. Effects of cholic acid on the metabolism of endogenous plasma triglyceride and on biliary lipid composition in hyperlipoproteinemia. J Lipid Res 1980; 21: 1-9.
36. Del Pozo R, Barth CA. Bile acids inhibit secretion of very low density lipoprotein by rat hepatocytes. Biol Chem Hoppe Seyler 1987; 368: 887-93.
37. Lin Y, Havinga R, Schippers IJ, et al. Characterization of the inhibitory effects of bile acids on very-low-density lipoprotein secretion by rat hepatocytes in primary culture. Biochem J 1996; 316: 531-8.
38. Lin Y, Havinga R, Verkade HJ, et al. Bile acids suppress the secretion of very-low-density lipoprotein by human hepatocytes in primary culture. Hepatology 1996; 23: 218-28.
39. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
40. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
41. Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50: 861-70.
42. Hernández M, Wright SD, Cai TQ. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 2007; 355: 1075-80.
43. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
44. Nervi F, Marinovic I, Rigotti A, Ulloa N. Regulation of biliary cholesterol secretion. Functional relationship between the canalicular and sinusoidal cholesterol secretory pathways in the rat. J Clin Invest 1988; 82: 1818-25.
45. Palou A, Remesar X, Arola L, Herrera E, Alemany M. Metabolic effects of short term food deprivation in the rat. Horm Metab Res 1981; 13: 326-30.
46. LeBoeuf RC, Caldwell M, Kirk E. Regulation by nutritional status of lipids and apolipoproteins A-I, A-II, and A-IV in inbred mice. J Lipid Res 1994; 35: 121-33.
47. Amigo L, Zanlungo S, Miquel JF, et al. Overexpression of sterol carrier protein 2 gene inhibits VLDL production and reciprocally enhances biliary lipid secretion. J Lipid Res 2003; 44: 399-407.
48. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 1980; 21: 284-91.
49. Carr TP, Andersen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993; 26: 39-42.
50. Zanlungo S, Amigo L, Mendoza H, et al. Sterol carrier protein 2 gene transfer changes lipid metabolism and enterohepatic sterol circulation in mice. Gastroenterology 2000; 119: 1708-19.
51. Nervi F, Del Pozo R, Covarrubias C, Ronco BO. The effect of progesterone on the regulatory mechanisms of biliary cholesterol secretion in the rat. Hepatology 1983; 3: 360-7.
52. Lowestein JM, Brunengraber H, Walke M. Measurement of rates of lipogenesis with deuterated and tritiated water. Methods Enzymol 1975; 35B: 279-87.
53. Dietschy JM, Spady DK. Measurement of rates of cholesterol synthesis using tritiated water. J Lipid Res 1984; 25: 1469-76.
54. De Wael J, Raaymakers CE, Endeman HJ. Simplified quantitative determination of total fecal bile salts. Clin Chim Acta 1977; 79: 465-70.
55. Yu L, Von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res 2004; 45: 301-7.
56. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
57. Li X, Catalina F, Grundy SM, Patel S. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48 relative to B-100-containing lipoproteins. J Lipid Res 1996; 37: 210-20.
58. Karpe F, Hamsten A. Determination of apolipoprotein B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994; 35: 1311-7.
59. Gromova I, Celis JE. Protein detection in gels by silver-staining: a procedure compatible with mass spectrometry. In: Celis JE, Carter N, Hunter T, Simons K, Small JV, Shotton D, eds. Cell Biology: A Laboratory Handbook, Vol. 1. Amsterdam: Elsevier, 2006; 219-24.
60. Blackhart BD, Ludwig EM, Pierotti VR, et al. Structure of the human apolipoprotein B gene. J Biol Chem 1986; 261: 15364-7.
61. Qu S, Perdomo G, Su D, et al. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res 2007; 48: 1476-87.
62. Lin X, Yue P, Xie Y, et al. Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation. Am J Physiol Gastrointest Liver Physiol 2005; 289: G146-52.
63. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate - phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
64. Davidson NO, Shelness GS. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93.
65. Purcell-Huynh DA, Farese RV Jr, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95: 2246-57.
66. Li X, Grundy SM, Patel SB. Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and differential secretion of apolipoprotein B-48 and B-100. J Lipid Res 1997; 38: 1277-88.
67. Cho H, Kang H, Choi S, et al. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol Pharm Bull 2005; 28: 1418-23.
68. Cho H, Kang H, Ju Y, et al. Augmentation of Ca2+-induced microsomal triglyceride transfer protein activity by glucose supply enhances hypertriglyceridemia in vivo. Biol Pharm Bull 2006; 29: 889-95.
69. Gordon DA, Jamil H, Sharp D, et al. Secretion of apolipoprotein B-containing lipoproteins from HeLa cells is dependent on expression of the microsomal triglyceride transfer protein and is regulated by lipid availability. Proc Nat Acad Sci (USA) 1994; 91: 7628-32.
70. Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009; 20: 206-10.
71. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-36.
72. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010; 1801: 209-14.
73. Thijs C, Knipschild P, Brombacher P. Serum lipids and gallstones: a case-control study. Gastroenterology 1990; 99: 843-9.
74. Juvonen T, Kervinen K, Kairaluoma MI, Kesäniemi YA. Effect of cholecystectomy on plasma lipid and lipoprotein levels. Hepatogastroenterology 1995; 42: 377-82.
75. Castro J, Amigo L, Miquel JF, et al. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 2007; 45: 1261-6.
76. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetes Med 2007; 24: 1-6.
77. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010; 1801: 299-10.